Malutiple-institutional observational surveillance of Pembrolizumab as a first line treatment for non-small cell lung cancer

Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2018
This article has no abstract
Epistemonikos ID: 00f02edb910898469da243dd39713aa971b75e0e
First added on: Apr 09, 2025